Dawaa Reference

chronic

Heart failure (chronic stable, reduced ejection fraction)

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources6 sources

ESC Guidelines for Heart Failure 2021 · Egyptian National Drug Formulary - Cardiovascular 2024 (carvedilol monograph) · Egyptian National Drug Formulary - Cardiovascular 2024 (spironolactone monograph) · Forxiga 10 mg film-coated tablets SmPC sections 4.1 and 4.2 (eMC product 7607) · UK eMC Furosemide 20 mg Tablets SmPC, product id 14911 · Egyptian National Drug Formulary - Cardiovascular 2024 (sacubitril and valsartan monograph)

Verified against8 documents
  • ESC Guidelines for Heart Failure 2021
  • Egyptian National Drug Formulary - Cardiovascular 2024 (carvedilol monograph)
  • Egyptian National Drug Formulary - Cardiovascular 2024 (spironolactone monograph)
  • Forxiga 10 mg film-coated tablets SmPC sections 4.1 and 4.2 (eMC product 7607)
  • UK eMC Furosemide 20 mg Tablets SmPC, product id 14911
  • Heart Failure (Congestive Heart Failure) - disease-level clinical article (heart-failure-clinical.txt)
  • Egyptian National Drug Formulary - Cardiovascular
  • Egyptian National Drug Formulary - Cardiovascular 2024 (sacubitril and valsartan monograph)

Verified date2026-08

Presentation reference

Is it this?

Reference only, to read alongside your own examination.

Symptoms — what the patient reports (9)

  • Breathlessness is the most reported symptom and should be classed as exertional, positional, or acute versus chronic [breathlessness]
  • Chest pain, poor appetite, and fatigue on exertion are also commonly reported [chest pain · fatigue · poor appetite]
  • Poor appetite stems from liver congestion, gut swelling, and reduced blood flow to the abdominal organs [poor appetite]
  • A cough that occurs while lying down can reflect orthopnea [cough · orthopnoea]
  • Abdominal discomfort can result from liver congestion or fluid in the abdomen [abdominal pain]
  • Palpitations, near-fainting, or fainting point to an underlying arrhythmia [arrhythmia · palpitations · syncope]
  • Leg swelling can impair mobility and balance, with weight gain over 20 lbs sometimes seen [leg swelling · weight gain]
  • Acute heart failure brings overt breathlessness, orthopnea, and sudden nighttime breathlessness [breathlessness · orthopnoea]
  • Chronic heart failure symptoms can be masked because patients scale back their activity

Signs — what you find (11)

  • Severe or acutely decompensated heart failure shows an anxious, sweaty, fast heart rate and fast breathing [anxiety · sweating · tachycardia · tachypnoea]
  • Chronic decompensated heart failure can leave patients looking wasted
  • Lung crackles signal heart failure of moderate to severe intensity [crackles]
  • Absent lung crackles do not rule out fluid in the lungs
  • Wheeze can appear in acute decompensated heart failure, with frothy, blood-tinged sputum as congestion worsens [sputum · wheeze]
  • Distended neck veins should be checked in every patient with heart failure [raised JVP]
  • A sustained rise of over 4 cm in neck vein pressure after pressing on the liver points to raised left heart filling pressure
  • Advanced heart failure can show low blood pressure, slow capillary refill, cold limbs, confusion, and reduced urine output [cold peripheries · confusion · hypotension]
  • An alternating strong-and-weak pulse points to severe ventricular dysfunction
  • A third heart sound is the earliest and most telling finding of heart failure
  • Valvular murmurs can accompany heart failure: pansystolic mitral or tricuspid regurgitation, an aortic stenosis ejection murmur, or an aortic regurgitation early diastolic murmur [heart murmur · stricture]

Tests (12)

  • A complete blood count may show anaemia or a raised white count pointing to an infection behind the decompensation
  • Kidney function is checked to set a baseline before starting RAAS inhibitors, SGLT2 inhibitors, or diuretics
  • Low blood sodium predicts higher in-hospital and 30-day mortality in heart failure
  • Liver congestion from heart failure can raise GGT, AST, and ALT
  • BNP or NT-proBNP helps separate a cardiac from a non-cardiac cause of breathlessness when the picture is unclear
  • BNP results can read misleadingly low in obesity, an underactive thyroid, or advanced disease
  • A QRS duration over 120 msec on ECG predicts response to device therapy
  • Chest x-ray signs of heart failure include an enlarged heart shadow, fluid at the lung bases, and vascular congestion
  • A normal chest x-ray does not exclude heart failure
  • Echocardiography is the first-choice bedside test for suspected heart failure
  • Cardiac catheterisation helps diagnose ischaemic cardiomyopathy and measure heart chamber pressures
  • Persistently raised troponin signals ongoing heart muscle injury and predicts worse outcomes

If not this — what else fits (8)

  • Heart failure must be differentiated from valvular heart disease
  • Heart failure must be differentiated from renal failure
  • Heart failure must be differentiated from acute respiratory distress
  • Heart failure must be differentiated from pulmonary fibrosis
  • Heart failure must be differentiated from nephrotic syndrome
  • Heart failure must be differentiated from pulmonary embolism
  • Heart failure must be differentiated from pericardial disease
  • Heart failure must be differentiated from cirrhosis

SourceStatPearls "Heart Failure (Congestive Heart Failure)" - disease-level clinical article

Presentation findings are traced to the source above.

Rx: Beta-blocker | Renin-angiotensin blocker | Mineralocorticoid antagonist | SGLT2 inhibitor | Main treatment | ARNI - renin-angiotensin agent for HFrEF | Congestion

BETA-BLOCKER - choose one

1

BISOPROLOL

Beta-blocker

1st line

Strength2.5 mg

Formoral.solid

Adult dose and duration

1.25 mg once daily, titrate slowly (doubling every 2+ weeks) to target 10 mg once daily - long-term

Paediatric dose

Specialist pediatric cardiology management required

Choice

Sourced preference. The entry's rationale names bisoprolol the beta-blocker of choice in the Egyptian formulary for heart failure with reduced ejection fraction.

Dose source

ESC Guidelines for Heart Failure 2021

Why

Beta-blocker of choice in Egyptian formulary for HFrEF

Cautions
  • CONTRAINDICATED in acute decompensated heart failure or cardiogenic shock.
  • Avoid in severe asthma or second/third-degree AV block.
  • Monitor blood pressure, heart rate, and fluid status during titration.
Egyptian brands
Egyptian brandManufacturerIndicative price
BISTOL 2.5MG 20 F.C.TAB.HIKMA PHARMA28.00 EGP (1.40/unit)
BISOLOCK 2.5 MG 30 F.C.TABS.PHARCO48.00 EGP (1.60/unit)
BISOCARD 2.5 MG 30 F.C.TAB.GLOBAL NAPI PHARMACEUTICALS51.00 EGP (1.70/unit)
NORMOCARD 2.5 MG 30 TAB.PHARMA CURE51.00 EGP (1.70/unit)
CONCOR COR 2.5 MG 30 F.C. TABS.AMOUN > MERCK KGAA F.R.GERMANY60.00 EGP (2.00/unit)
2

CARVEDILOL

Beta-blocker

1st line

Strength6.25 mg

Formoral.solid

Adult dose and duration

3.125 mg twice daily initially, doubled at intervals of at least 2 weeks as tolerated. Maximum 25 mg twice daily if 85 kg or less or in severe heart failure; 50 mg twice daily if over 85 kg - Long-term

Paediatric dose

Effectiveness in patients under 18 years has not been established.

Dose source

Egyptian National Drug Formulary - Cardiovascular 2024 (carvedilol monograph)

Why

25 live products. Chronic heart failure is the formulary's first listed indication. Combined alpha and beta blockade lowers blood pressure more than the bisoprolol already listed, which suits the very common Egyptian patient who has heart failure and uncontrolled hypertension together.

Cautions
  • Use one beta-blocker only - carvedilol is an alternative to the bisoprolol in this row, never an addition.
  • CONTRAINDICATED in bronchial asthma, acute or decompensated heart failure requiring intravenous inotropes, second- or third-degree AV block, severe bradycardia without a pacemaker, sick sinus syndrome, cardiogenic shock and severe hepatic disease.
  • Expect transient worsening of symptoms and hypotension in the first 2 weeks - warn the patient, do not abandon the drug, and increase the diuretic temporarily if needed.
  • Never start during an acute decompensation and never stop abruptly.
  • Avoid in severe hepatic impairment; moderate impairment may need a dose reduction.
  • Masks the adrenergic warning signs of hypoglycaemia in an insulin-treated patient.
Egyptian brands
Egyptian brandManufacturerIndicative price
VIDILOL 6.25 MG 10 TABS.MEMPHIS3.50 EGP (0.35/unit)
CARLOL-V 6.25MG 30 F.C.TABAMOUN19.50 EGP (0.65/unit)
KARVEX 6.25MG 30 TAB.SIGMA19.50 EGP (0.65/unit)
CARDILOL 6.25MG 30 TAB.MARCYRL PHARMACEUTICAL INDUSTRIES (MPI)39.00 EGP (1.30/unit)
CARVID 6.25MG 20 TAB.MULTI-APEX30.00 EGP (1.50/unit)
CARVID 6.25MG 30 TAB.MULTI-APEX45.00 EGP (1.50/unit)
DILATROL 6.25MG 30 TAB.CHEMIPHARM48.00 EGP (1.60/unit)
CARVIPRESS 6.25MG 20 SCORED TAB.GLOBAL NAPI PHARMACEUTICALS13.00 EGP

RENIN-ANGIOTENSIN BLOCKER

3

ENALAPRIL

Renin-angiotensin blocker

1st line

Strength5 mg

Formoral.solid

Adult dose and duration

2.5 mg BID initially, titrate to target 10-20 mg BID - long-term

Paediatric dose

Specialist pediatric cardiology management required

Dose source

ESC Guidelines for Heart Failure 2021

Why

ACE inhibitor combined with beta-blocker to reduce mortality

Cautions
  • CONTRAINDICATED in pregnancy.
  • Check serum creatinine and potassium within 1-2 weeks of initiation.
  • Caution in renal artery stenosis or eGFR < 30 mL/min.
  • If a RAAS agent cannot be used at all, the article offers a combination this card does NOT carry: "For patients with HFrEF and intolerance to RAASI or in whom RAASI is contraindicated due to renal insufficiency, the use of a combination of hydralazine and nitrate might be effective."
  • Hydralazine is deliberately not offered here. The Egyptian formulary indicates it for "Hypertension, chronic: Management of moderate to severe hypertension." only, states no heart-failure dose anywhere, and contraindicates it outright: "Cardiovascular disease: Use is contraindicated in patients with coronary artery disease (CAD)." - adding that "myocardial stimulation produced by hydralazine can cause anginal attacks and electrocardiogram (ECG) changes of myocardial ischemia; has been implicated in the production of myocardial infarction." Ischaemic heart disease is the commonest cause of the heart failure on this card, so that contraindication is not a rare edge case.
Egyptian brands
Egyptian brandManufacturerIndicative price
ACAPRIL 5 MG 10 TAB.ALFACURE PHARMACEUTICALS6.75 EGP (0.68/unit)
PRESSLIGHT 5 MG 10 TAB.EL-OBOUR7.00 EGP (0.70/unit)
RENITEC 5MG 28 TAB.GLOBAL NAPI PHARMACEUTICALS > MERCK SHARP & DOHME30.60 EGP (1.09/unit)

MINERALOCORTICOID ANTAGONIST

4

SPIRONOLACTONE

Mineralocorticoid antagonist

1st line

Strength25 mg

Formoral.solid

Adult dose and duration

12.5-25 mg once daily, adjusted every 4 weeks if potassium and kidney function are stable, to a maximum of 50 mg/day - long-term

Paediatric dose

Specialist paediatric cardiology management. The formulary's paediatric spironolactone doses are for oedema, hypertension and primary aldosteronism, not for HFrEF.

Dose source

Egyptian National Drug Formulary - Cardiovascular 2024 (spironolactone monograph)

Why

One of the four drugs NICE says to offer together in HFrEF. Note the dose: 25 mg, not the 100 mg used for cirrhotic ascites. Writing the ascites dose in heart failure is a hyperkalaemia admission.

Cautions
  • Given WITH the beta-blocker, the ACE inhibitor and the SGLT2 inhibitor, not instead of any of them - NICE offers all four.
  • Check potassium and creatinine before starting, at 1 and 4 weeks after each dose change, then regularly. Stop if potassium exceeds 6.0 mmol/L.
  • Avoid the combination of spironolactone with an ACE inhibitor plus a potassium supplement or a potassium-containing salt substitute - that is the classic route to a fatal potassium.
  • Painful gynaecomastia in men is common and is the usual reason for stopping.
  • The heart failure dose is 25 mg. The ascites dose is 100 mg. They are not interchangeable.
Egyptian brands
Egyptian brandManufacturerIndicative price
SPIRONOLACTONE (DELTA) 25MG 10 TAB.GLOBAL NAPI PHARMACEUTICALS > AL DELTA PHARMACEUTICALS TRADING CO.3.00 EGP (0.30/unit)
EPILACTONE 25MG 10 TAB.EIPICO4.00 EGP (0.40/unit)
POTASAVE 25 MG 20 TAB.ALFACURE PHARMACEUTICALS11.00 EGP (0.55/unit)
ALDACTONE 25MG 20 TABKAHIRA > SEARLE-CANADA18.00 EGP (0.90/unit)
POTASPIRONO 25 MG 20 TAB.UNIPHARMA36.00 EGP (1.80/unit)
SPECTONE 25 MG 20 TABS.KAHIRA36.00 EGP (1.80/unit)

SGLT2 INHIBITOR

5

DAPAGLIFLOZIN

SGLT2 inhibitor

1st line

Strength10 mg

Formoral.solid

Adult dose and duration

10 mg once daily - long-term

Paediatric dose

Not established in children for heart failure.

Dose source

Forxiga 10 mg film-coated tablets SmPC sections 4.1 and 4.2 (eMC product 7607)

Why

The fourth pillar, and the one most often left off an Egyptian heart-failure prescription. It is licensed for symptomatic chronic heart failure in its own right - the patient does not need to be diabetic.

Cautions
  • Not a diabetes drug here. It is given for the heart failure whether or not the patient has diabetes, and it is licensed for that.
  • No dose titration - 10 mg once daily is the dose.
  • Genital mycotic infection and urinary tract infection are common; counsel on hygiene at the first prescription.
  • Euglycaemic diabetic ketoacidosis is rare but is missed because the glucose looks normal - think of it in any unwell patient on an SGLT2 inhibitor with acidosis.
  • Sick-day rules: hold it during vomiting, diarrhoea or any dehydrating illness, especially alongside the ACE inhibitor and the diuretic.
  • Expect a small early fall in eGFR. That is not a reason to stop.
Egyptian brands
Egyptian brandManufacturerIndicative price
DAPABLIX 10 MG 30 F.C. TABS.AL ESRAA PHARMACEUTICAL OPTIMA186.00 EGP (6.20/unit)
DEXIGLOFOZIN 10 MG 30 F.C. TABS.ZETA PHARMA195.00 EGP (6.50/unit)
GLIFLOZINO 10 MG 30 F.C.TABSINSPIRE PHARMACEUTICAL COMPANY214.50 EGP (7.15/unit)
DAPAGLIFLOZIN-EVA 10 MG 30 F.C. TABS.EVA PHARMA271.50 EGP (9.05/unit)
ZEGAPETS 10 MG 28 F.C. TABS.OCTOBER PHARMA280.00 EGP (10.00/unit)
DIGLIFLOZ 10 MG 30 F.C. TABS.MARCYRL318.00 EGP (10.60/unit)
DAPAVELDACTIN 10 MG 28 F.C. TABS.LIPTIS368.00 EGP (13.14/unit)
FORXIGA 10 MG 28 TABS.ASTRA ZENECA602.00 EGP (21.50/unit)

MAIN TREATMENT - choose one, plus any add-on marked below

6

REFERRAL & SAFETY-NETTING (NO DRUG THERAPY)

1st line
Dose source

Heart Failure (Congestive Heart Failure) - disease-level clinical article (heart-failure-clinical.txt)

Why

Carries the referral criteria and warning signs for this condition, which apply whichever treatment is chosen.

Cautions
  • RED FLAG - Recognize the common triggers of acute decompensation in a chronic HFrEF patient (infection, medication noncompliance, NSAID use, increased salt intake), which need to prompt a different response than routine chronic management.
7

VALSARTAN

1st line

Strength40 mg

Formoral.solid

Adult dose and duration

Initial: 20 to 40 mg twice daily; increase dose after at least 2 weeks based on response and tolerability up to a 160 mg twice daily. - long-term

Paediatric dose

No paediatric heart failure dose in the monograph. For hypertension (6 months to 16 years): 1 to 2 mg/kg/dose once daily initially; max 4 mg/kg/day (not to exceed 160 mg/day).

Dose source

Egyptian National Drug Formulary - Cardiovascular

Why

Angiotensin II receptor blocker used as a first-line alternative agent in HFrEF for patients unable to tolerate ACE inhibitors.

Cautions
  • CONTRAINDICATED in pregnancy.
  • Monitor blood pressure, serum potassium, and kidney function closely following initiation and dose increases.
Egyptian brands
Egyptian brandManufacturerIndicative price
VALSATENS 40MG 30 F.C. TAB.AMOUN45.00 EGP (1.50/unit)
LASAROMEP 40MG 10 F.C. TAB.MEPACO17.50 EGP (1.75/unit)
TAREG 40MG 15 F.C.TAB.NOVARTIS150.00 EGP (10.00/unit)
VASOTEC 40 MG 14 SCORED F.C. TABS.EIPICO32.00 EGP
8

IVABRADINE

add-on - not a substitute

Strength5 mg

Formoral.solid

Adult dose and duration

Initial: 5 mg twice daily or 2.5 mg twice daily in patients with a history of conduction defects or who may experience hemodynamic compromise due to bradycardia. Adjust dose every ≥2 weeks as needed. - long-term

Paediatric dose

0.05-0.3 mg/kg/dose [child max 7.5 mg]

(Children ≥6 months (heart failure, dilated cardiomyopathy): <40 kg: 0.05 mg/kg/dose twice daily initially, titrate by 0.05 mg/kg/dose every 2 weeks; max 0.2 mg/kg/dose twice daily (<1 year)

or 0.3 mg/kg/dose twice daily (≥1 year, max 7.5 mg/dose). ≥40 kg:

2.5 mg twice daily, titrate by 2.5 mg every 2 weeks; max 7.5 mg

twice daily.)

Dose by weight
3kg0.15-0.9 mg/dose
4kg0.2-1.2 mg/dose
5kg0.25-1.5 mg/dose
6kg0.3-1.8 mg/dose
7kg0.35-2.1 mg/dose
8kg0.4-2.4 mg/dose
9kg0.45-2.7 mg/dose
10kg0.5-3 mg/dose
11kg0.55-3.3 mg/dose
12kg0.6-3.6 mg/dose
13kg0.65-3.9 mg/dose
14kg0.7-4.2 mg/dose
15kg0.75-4.5 mg/dose
16kg0.8-4.8 mg/dose
17kg0.85-5.1 mg/dose
18kg0.9-5.4 mg/dose
19kg0.95-5.7 mg/dose
20kg1-6 mg/dose
21kg1.1-6.3 mg/dose
22kg1.1-6.6 mg/dose
23kg1.2-6.9 mg/dose
24kg1.2-7.2 mg/dose
25kg1.2-7.5 mg/dose
26kg1.3-7.5 mg/dose (upper capped)
27kg1.4-7.5 mg/dose (upper capped)
28kg1.4-7.5 mg/dose (upper capped)
29kg1.5-7.5 mg/dose (upper capped)
30kg1.5-7.5 mg/dose (upper capped)
31kg1.6-7.5 mg/dose (upper capped)
32kg1.6-7.5 mg/dose (upper capped)
33kg1.7-7.5 mg/dose (upper capped)
34kg1.7-7.5 mg/dose (upper capped)
35kg1.8-7.5 mg/dose (upper capped)
36kg1.8-7.5 mg/dose (upper capped)
37kg1.9-7.5 mg/dose (upper capped)
38kg1.9-7.5 mg/dose (upper capped)
39kg2-7.5 mg/dose (upper capped)
40kg2-7.5 mg/dose (upper capped)
41kg2.1-7.5 mg/dose (upper capped)
42kg2.1-7.5 mg/dose (upper capped)
43kg2.1-7.5 mg/dose (upper capped)
44kg2.2-7.5 mg/dose (upper capped)
45kg2.2-7.5 mg/dose (upper capped)
46kg2.3-7.5 mg/dose (upper capped)
47kg2.4-7.5 mg/dose (upper capped)
48kg2.4-7.5 mg/dose (upper capped)
49kg2.5-7.5 mg/dose (upper capped)
50kg2.5-7.5 mg/dose (upper capped)
Dose source

Egyptian National Drug Formulary - Cardiovascular

Why

Selective sinus node I(f) inhibitor added to reduce heart failure hospitalizations in patients in sinus rhythm with resting HR >= 70 bpm on maximum beta-blocker.

Cautions
  • Use increases the risk of atrial fibrillation; monitor cardiac rhythm.
  • Bradycardia, sinus arrest, and heart block may occur; monitor heart rate prior to initiation and with any dosage adjustment.
Egyptian brands
Egyptian brandManufacturerIndicative price
SAVAPRAN 5 MG 20 F.C. TABS.HORUS FOR PHARMACEUTICAL PRODUCTS > EVA PHARMA98.66 EGP (4.93/unit)
WADIBRADIN 5 MG 20 F.C. TABS.WADI ELNEEL BENTA116.00 EGP (5.80/unit)
BRADIPECT 5 MG 28 F.C.TABS.OCTOBER PHARMA168.00 EGP (6.00/unit)
IVABRAGIN 5 MG 30 F.C. TABS.P & C LABS234.00 EGP (7.80/unit)
NAPIBRADINE 5 MG 30 F.C. TABS.GLOBAL NAPI PHARMACEUTICALS234.00 EGP (7.80/unit)
PROCORALAN 5MG 28 F.C. TABS.SERVIER352.00 EGP (12.57/unit)
ANGIOBRADINE 5 MG 30 SCORED F.C.TABS.FUTURE PHARMACEUTICAL INDUSTRIES (FPI) > TABUK PHARMA166.00 EGP
ADWISTADINE 5 MG 30 SCORED F.C.TABS.ADWIA178.50 EGP

ARNI - RENIN-ANGIOTENSIN AGENT FOR HFREF

9

SACUBITRIL + VALSARTAN

ARNI - renin-angiotensin agent for HFrEF

1st line

Strength100 mg

Formoral.solid

Adult dose and duration

Initially 50 mg twice daily for 3 to 4 weeks if not already on an ACE inhibitor or ARB, or 100 mg twice daily if stabilised on one; doubled at 3 to 4 week intervals if tolerated, up to 200 mg twice daily. Start at 50 mg twice daily if the systolic blood pressure is below 110 mmHg

Paediatric dose

Not applicable - the ENDF gives no paediatric dose for this combination.

Dose source

Egyptian National Drug Formulary - Cardiovascular 2024 (sacubitril and valsartan monograph)

Why

The article makes an ARNI the recommended renin-angiotensin agent in HFrEF, ahead of an ACE inhibitor, with an ACE inhibitor or ARB kept for patients who cannot afford it - and the card's valsartan row is an ARB, not an ARNI. The ENDF monograph names symptomatic chronic heart failure with reduced ejection fraction as its indication and doses it. This REPLACES the card's enalapril or valsartan; it is never added to them.

Cautions
  • Concomitant use with an ACE inhibitor (do not initiate until at least 36 hours after discontinuing ACE inhibitor - risk of angioedema). Concomitant use with an angiotensin II receptor antagonist.
  • This card also carries enalapril and valsartan: sacubitril + valsartan replaces either of them and must never be given alongside one.
  • History of angioedema related to previous ACE inhibitor or ARB (angiotensin receptor blocker) therapy; systolic blood pressure less than 100 mmHg
  • Concomitant use of aliskiren in patients with diabetes or renal disease; pregnancy; lactation
  • Severe hepatic impairment, biliary cirrhosis or cholestasis: avoid (has not been studied).
Egyptian brands
Egyptian brandManufacturerIndicative price
ENTRESTO 100 MG (49/51 MG) 28 F.C.TABS.NOVARTIS1700.00 EGP (60.71/unit)

CONGESTION - give alongside

10

FUROSEMIDE

Congestion

add-on - not a substitute

Strength40 mg

Formoral.solid

Adult dose and duration

20-40 mg once daily in the morning (or divided BID), titrate based on fluid overload and symptom response - long-term

Paediatric dose

Specialist pediatric cardiology management required

Dose source

UK eMC Furosemide 20 mg Tablets SmPC, product id 14911

Why

Loop diuretic added for symptomatic relief of congestion

Cautions
  • Monitor electrolytes (potassium, sodium) and renal function regularly.
  • Caution in gout or severe hepatic impairment.
  • There is a risk of hypotension and hypovolaemia.
Egyptian brands
Egyptian brandManufacturerIndicative price
ODEMENT 40MG 10 TAB.EL NASR1.30 EGP (0.13/unit)
FRUZEX 40MG 12 TAB.MISR3.25 EGP (0.27/unit)
FUROSEMIDE 40MG 20 TAB.SEDICO7.50 EGP (0.38/unit)
FURORETIC 40 MG 30 TABS.DEBEIKY > VETOPHARM14.25 EGP (0.47/unit)
LAFUREX 40MG 20 TAB.AMOUN9.50 EGP (0.47/unit)
SALEX 40 MG 20 TABS.ARAB DRUG COMPANY (ADCO)10.00 EGP (0.50/unit)
FUROSEMIDE-ALEX 40MG 20 TAB.ALEXANDRIA19.00 EGP (0.95/unit)
LASIX 40 MG 24 TABS.SANOFI30.00 EGP (1.25/unit)
GENESEMIDE 20MG/5ML SYRUP 120 ML? strength differs? different route - not oral solidMEDIZEN PHARMACEUTICAL INDUSTRIES > VODACHEM56.00 EGP

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.